Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for AURKA drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Active Kinase | AURKA Kinase Domain / Mutant Proteins High purity (>95%), Endotoxin <1 EU/ug. Sequence Verified. Theoretical MW confirmed. |
View AURKA Products |
| Gene Delivery | AURKA Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View AURKA Products |
| Assay Control | Anti-AURKA Recombinant Antibody Set Total & Phospho-Thr288 for Western/IF validation. |
View AURKA Products |
| Validator | AURKA siRNA Set For knockdown and specificity verification. >85% mRNA reduction. |
View AURKA Products |
| Isoform Selectivity (AURKB) | AURKB Kinase Domain Protein Essential off-target counter-screen for inhibitor selectivity. >95% purity. |
View AURKB Products |
| Isoform Selectivity (AURKC) | AURKC Kinase Domain Protein Testis-specific isoform for selectivity profiling. High purity. |
View AURKC Products |
| Complex Partner | TPX2 (Targeting Protein for Xklp2) AURKA activator; required for conformation-specific inhibitor assays. |
View TPX2 Products |
| Synthetic Lethality | PLK1 (Polo-like Kinase 1) Cell-cycle pathway partner for combination therapy research. |
View PLK1 Products |
Critical Assay Challenges and TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| AURKB/AURKC Selectivity Counter-screen | Human AURKA, AURKB, and AURKC Kinase Domain proteins available; >95% purity; Sequence Verified for ortholog alignment |
| Drug Resistance & Gatekeeper Mutations | AURKA Mutant Recombinant Panel (gatekeeper and activation loop variants: G216R, E211K, V247I); Theoretical MW confirmed; Endotoxin Controlled |
| Lack of Cellular Assay Controls | AURKA Lentivirus ORF and Validated siRNA Set for target engagement confirmation |
| TPX2-Dependent Conformation States | Active AURKA-TPX2 Complex Protein; HEK293 Expressed for native folding |
| PROTAC Ternary Complex Validation | High-purity recombinant proteins optimized for SPR and biochemical binding assays; sequence-verified siRNA included for precise target specificity checks |
Live AURKA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for AURKA therapeutics is intensifying, with major players shifting focus from first-generation pan-Aurora inhibitors (e.g., Takeda's Alisertib) to next-generation AURKA-selective small molecules and targeted protein degradation strategies. Alisertib's dose-limiting toxicities due to off-target AURKB inhibition have driven a paradigm shift toward highly selective inhibitors (e.g., Bayer BAY-1895344, Eli Lilly LY3295668) and emerging modalities such as PROTACs and allosteric modulators. As early-generation therapies define clinical benchmarks, the next wave of R&D is targeting resistance mutations (gatekeeper and activation loop), synthetic lethal combinations (e.g., with PLK1 or CDK4/6 inhibitors), and TPX2-dependent conformation states to broaden the therapeutic index.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Selective Small Molecule Inhibitor | Bayer (BAY-1895344), Nerviano/Menarini (NMS-P118), Eli Lilly (LY3295668) | Breast, Ovarian, Neuroblastoma, Lung | Selectivity Assay (Need AURKA vs AURKB vs AURKC Kinase Domains) |
| Pan-Aurora Inhibitor | Takeda (Alisertib/MLN8237) | PTCL, SCLC, Solid Tumors | Safety Counter-screen (Need active AURKB to model hematologic toxicity) |
| Allosteric Inhibitor | Preclinical (Academic/BI) | Solid Tumors, MYC-driven Cancers | TPX2-AURKA complex protein for binding assays |
| PROTAC / Degrader | Emerging Biotech (Arvinas, Cullgen) | Solid Tumors, Refractory Cancers | Cellular Stability Assay & Ternary Complex Assay (Need Lentivirus ORF and high-purity kinase domains) |
| Combination Regimen | Academic / Pharma Consortia (Paclitaxel, CDK4/6i combos) | Ovarian, TNBC, Chemoresistant | Resistance Profiling (Need Mutant Kinase Panel for preclinical screening) |